A correspondence published in The Lancet has drawn renewed scientific attention to Andes virus — the only member of the Hantaviridae family known to spread efficiently between people — following an outbreak aboard a Dutch cruise ship that researchers have characterised as unlike anything previously recorded in the virus's known history.
An Unprecedented Transmission Setting
The MV Hondius, which had departed from Argentina in May 2026, became the site of what The Lancet correspondence describes as a transmission context unprecedented in Andes virus epidemiology. While the pathogen was first identified in Argentina and has caused documented outbreaks there, its appearance aboard a vessel at sea — an enclosed, mobile environment — represents a departure from the settings in which the virus has historically been tracked.
Unlike other members of the Hantaviridae family, which typically reach human hosts through contact with infected rodent material, Andes virus is capable of moving directly from person to person via close contact with respiratory secretions. That biological distinction makes outbreak containment considerably more complex and has long positioned the virus as a priority pathogen in infectious disease surveillance.
Context: The Epuyén Outbreak
To understand the significance of the MV Hondius event, the correspondence situates it against prior Argentine outbreaks. The 2018–19 Epuyén cluster remains among the most studied examples of Andes virus person-to-person transmission. That outbreak unfolded across four successive waves of infection, all traceable to exposure at a single social gathering — a pattern that illustrated how rapidly the virus can propagate through close-contact networks. By the time the Epuyén outbreak concluded, 34 confirmed cases had been recorded and 11 people had died, according to data cited in the correspondence.
The scale and multi-wave structure of Epuyén underscored the difficulty of interrupting Andes virus transmission once it gains a foothold in a social cluster. A confined vessel environment, where passengers and crew share dining areas, ventilation systems, and common spaces over extended periods, would present analogous — and potentially amplified — challenges.
The Case for mRNA Vaccines
Against this backdrop, the Lancet correspondence raises the question of single-dose mRNA vaccines as a potential countermeasure. The mRNA platform, which demonstrated rapid development timelines and adaptability during the COVID-19 pandemic, has since been explored for application against a range of emerging and neglected pathogens. For a virus like Andes, where outbreaks can escalate quickly and geographic remoteness has historically complicated response logistics, a single-dose regimen would carry practical advantages — particularly in settings where follow-up vaccination is difficult to guarantee.
The correspondence does not report clinical trial data for an Andes-specific mRNA vaccine but frames the MV Hondius outbreak as a prompt for accelerating that research agenda. The argument rests partly on the virus's unique transmission profile within its family and partly on the demonstrated capacity of Andes virus outbreaks to cause high case-fatality rates in relatively short timeframes.
Broader Implications for Hantavirus Preparedness
Andes virus has long occupied an unusual position in hantavirus research — dangerous enough to attract scientific interest, yet geographically contained enough to remain underfunded relative to pathogens with wider global reach. The appearance of a confirmed outbreak in a mobile, international travel setting may shift that calculus. Cruise ships, by their nature, carry passengers from multiple countries and dock at multiple ports, creating pathways for onward spread that land-based outbreaks in remote Patagonian communities do not.
Whether the MV Hondius event will translate into sustained investment in Andes virus vaccine development remains to be seen. What the Lancet correspondence makes clear is that the epidemiological conditions for a more expansive outbreak now exist, and that the scientific tools to address them — including mRNA vaccine technology — are closer to hand than they were during previous outbreaks.